A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer

This study has been terminated.
(The sponsor terminated funding for the study.)
Bristol-Myers Squibb
Information provided by (Responsible Party):
Olga Castellanos, Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier:
First received: May 1, 2008
Last updated: September 3, 2014
Last verified: September 2014

The purpose of this research study is to determine the safety and effectiveness of the investigational drug, Ixabepilone, in men with high risk prostate cancer who plan to receive surgery.

Prostate cancer is a common and important health issue facing men in the United States. Most patients with prostate cancer are identified when the disease is limited to the prostate gland itself (localized prostate cancer). A standard treatment for some patients with localized prostate cancer is removal of the prostate gland in an operation known as a "radical prostatectomy." A sub-set of patients with localized prostate cancer can be identified who are at high-risk of suffering a recurrence of prostate cancer after radical prostatectomy. For these patients, additional treatments are being investigated to combine with surgery in the hopes of increasing the chances for cure.

Several kinds of chemotherapy medicines have been used for advanced prostate cancer which returns after initial therapy. Epothilones are a newly developed class of chemotherapy drugs that appear promising for the treatment of many forms of cancer. Ixabepilone is drug in the epothilone class of chemotherapy medicines that has shown encouraging results for the treatment of advanced prostate cancer and other cancers in clinical trials.

This trial will include men with high-risk localized prostate cancer who will receive treatment with ixabepilone (4 cycles over 12 weeks) prior to radical prostatectomy. The goal of this trial will be to determine if analysis of genes and proteins in prostate cancer tissue taken before and after treatment can be used to predict ixabepilone response. In addition, this trial will evaluate the safety and feasibility of administering ixabepilone prior to radical prostatectomy for patients at high-risk of developing recurrent prostate cancer.

The study has three phases: Screening, Treatment and Follow-up

  • Screening: Eligibility will be verified
  • Treatment: Subjects will receive Ixabepilone, which will be administered every 21 days for 4 cycles prior to surgery
  • Follow up: Subjects will be followed every 6 months for up to 5 years.

In addition, tissue will be collected at the time of surgery for genetic and protein studies. Blood will also be collected pre and post therapy for proteomic and/or genetic studies.

Condition Intervention Phase
Prostatic Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms
Neoplasms, Glandular and Epithelial
Drug: Ixabepilone
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Cedars-Sinai Medical Center:

Primary Outcome Measures:
  • To determine the biochemical response rate (defined as >/= 50% reduction in PSA from baseline to the post-therapy value) for non-castrate patients with localized prostate cancer and a >/= 30% risk of recurrence within 5 years. [ Time Frame: 4 cycles ] [ Designated as safety issue: No ]

Enrollment: 11
Study Start Date: April 2008
Study Completion Date: August 2012
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: One Drug: Ixabepilone
Ixabepilone 35 mg/m^2 intravenously over 3 hours every 21 days for 4 cycles.
Other Name: BMS-247550


Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically-confirmed localized prostate cancer
  • Predicted probability of recurrence >/= 30% as defined by the updated Kattan nomogram
  • Pathologic material available for gene expression analysis including cancer present in 2 or more cores and availability of unstained slides or formalin-fixed paraffin embedded tissue blocks.
  • No prior prostate cancer therapy (including hormonal, chemotherapy, radiation or surgery)
  • Subjects must be considered as candidates for radical prostatectomy
  • EGOG status
  • Men of child-bearing potential are required to use an effective means of contraception
  • Required Initial Laboratory Values:
  • ANC >/= 1500/uL
  • Platelet Count >/= 100000/uL
  • Creatinine Bilirubin AST < 2.5 X ULN
  • ALT < 2.5 X ULN
  • Hemoglobin >/= 9.0 g/dL

Exclusion Criteria:

  • A history of significant ventricular arrhythmias
  • Neuropathy (> grade 1)
  • Recent (within 6 months) myocardial infarction, congestive heart failure, transient ischemic attack or stroke
  • Active angina, including active stable and unstable angina
  • Acute deep venous thrombosis and/or pulmonary embolism in the past 6 months
  • Any prior hormonal therapy including the use of PC Spes or estrogen containing nutriceuticals
  • Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma.
  • Patients with malignancy diagnosed more than 5 years ago and are disease free for at least 5 years are not excluded.
  • Recent (within 4 weeks) surgery or incomplete healing from surgery
  • Known history of hypersensitivity reaction to a drug formulated in Cremophor EL
  • Treatment with a non-approved or investigational drug within 30 days before Day 1 of trial treatment
  • Active infection requiring antibiotic therapy, or serious intercurrent illness.
  • Any other major illness that in the investigators judgment will substantially increase the risk associated with the subject's participation in this study.
  • Unwillingness or inability to comply with procedures required in this protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00672009

United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Sponsors and Collaborators
Cedars-Sinai Medical Center
Bristol-Myers Squibb
Principal Investigator: Mitchell E Gross, MD, PhD Cedars-Sinai Medical Center
  More Information

No publications provided

Responsible Party: Olga Castellanos, Mitchell Gross, MD, PHD Director of Research, Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier: NCT00672009     History of Changes
Other Study ID Numbers: 13963 
Study First Received: May 1, 2008
Last Updated: September 3, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Cedars-Sinai Medical Center:
prostate cancer
radical prostatectomy

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms, Glandular and Epithelial
Prostatic Diseases
Prostatic Neoplasms
Urogenital Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site

ClinicalTrials.gov processed this record on February 09, 2016